Methods of Modulating Fibrosis
Description: The invention features a novel approach to the modulation of the cellular pathways leading to fibrosis and extracellular matrix deposition. Connective tissue growth factor (CTGF) is known to be a potent activator of fibrosis, angiogenesis and extracellular matrix production. The invention is based on the finding that a different growth factor regulates CTGF activity through a particular signal transduction pathway. Decreasing the activity of this other growth factor, or of key intermediates in the signal transduction pathway, leads to decreased CTGF activity and decreased fibrosis or decreased angiogenesis. Conversely, fibrosis and angiogenesis can be increased, where desired, by use of agents that increase the activity of the growth factor or pathway intermediates. Clinical & Commercial Utility: The invention therefore provides novel potential strategies for the modulation of fibrosis or angiogenesis, using agents that modulate the various factors that affect CTGF activity through the newly-identified pathway. Inhibitors of this pathway can be used to inhibit fibrosis, for example in disorders like scleroderma, pulmonary fibrosis or scarring. Activators of the pathway may be used to promote fibrosis, for example in the case of wound healing. The pathway may also be modulated to modulate angiogenesis, perhaps as a cancer treatment. Finally, the invention provides new screening methods to identify drug candidates for any of these types of diseases.Joslin Diabetes Center is the owner of U.S. Patent Number 7,175,844 claiming this invention.
Type of Offer: Licensing
« More Medical Patents